2013-03-14 19:33:02 - Leading provider of advanced cell-based screening technologies and services, Cellectricon announced today that it has expanded its sales and service network into Asia.

The company signed a distribution agreement for its Dynaflow® line with Japan-based Novel Science Co., Ltd. In addition, Nepa Gene Co., Ltd., will distribute Cellectricon’s Cellaxess® ACE system and module in Japan.

The Dynaflow Resolve system is an add-on to your existing patch-clamp setup that offers automated solution exchange with high speed, control, and flexibility. The system has an extremely broad application base and is an ideal platform for advanced patch-clamp experiments. Cellaxess ACE is a single electrode-based electroporation system that can be used for any adherent cell type. Cellaxess electroporation offers superior transfection quality because of minimal cell processing.

Novel Science Co., Ltd., serves a range of life science research customers, providing both instruments and consumable reagents. The company

specializes in tools for electrophysiology research. Kazuhiko Hiraoka President, commented: "At Novel Science, we contribute to biotechnology advancement by importing and supplying leading edge ion channel research tools. Dynaflow Resolve will help us improve our range of offerings for our customers in cellular research.”

Nepa Gene Co., Ltd., is as supplier of electroporation, electro cell-fusion, and sonoporation equipment. With more than thirty years of experience, Nepa Gene is one of the leading suppliers of high quality instruments for the Life science industry. ”Cellaxess ACE nicely complements our existing product range,” said Mr Yasuhiko Hayakawa, President of Nepa Gene.

“We are confident that these two leading distributors will help us expand our research and drug discovery systems into the rapidly growing Japanese market,” said Mattias Karlsson, VP Business Development at Cellectricon.

Cellectricon is a leading provider of advanced cell-based screening technologies and services to accelerate drug discovery and cell-based assay research. Our proprietary technologies include leading systems for high resolution ion-channel screening and cell engineering. Developed in close collaboration with leaders in the pharmaceutical industry and esteemed research labs, the Cellaxess Technology enables field stimulation, compound delivery and transfection for genomic screening of primary cells, and stem cells. The Dynaflow Technology advances ion channel research and discovery applications.

For more information on Cellectricon, visit www.cellectricon.com